DNA image cytometry is a useful adjunct tool in the prediction of disease outcome in patients with stage II and stage III colorectal cancer

Oncology

Volumn 70, Issue 6, 2007, Pages 427-437

  Buhmeida, A ^a   Algars A ^a   Ristamaki R ^a   Collan, Y ^a   Syrjanen K ^a   Pyrhonen S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adjuvant therapy, patient selection; Colorectal cancer, prognosis; Nuclear DNA content

Indexed keywords

CELL NUCLEUS DNA; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; CELL ISOLATION; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOMETRY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FEULGEN STAINING; HAPLOIDY; HISTOGRAM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; HAPLOIDY; HUMANS; IMAGE CYTOMETRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS;

EID: 33847365344     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098556     Document Type: Article

References (60)

1. Gatta G, Faivre J, Capocaccia R, Ponz de Leon M: Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 1998;34:2176-2183.
2. Repetto L, Venturino A, Fratino L, et al: Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 2003;39:870-880.
3. Wymenga AN, Slaets JP, Sleijfer DT: Treatment of cancer in old age, shortcomings and challenges. Neth J Med 2001;59:259-266.
4. Franceschi S, La Vecchia C: Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 2001;39:219-226.
5. Donohue JH, Williams S, Cha S, et al: Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. J Clin Oncol 1995;13:1671-1678.
6. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 2001;51:144.
7. Steele G Jr, Ravikumar TS, Benotti PN: Surgical treatments for recurrent colorectal cancer. Cancer 1990;65:723-730.
8. Bruckner HW, Motwani BT: Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 1991;18:443-461.
9. Berberoglu U: Prognostic significance of total lymph node number in patients with T1-4N0M0 colorectal cancer. Hepatogastroenterology 2004;51:1689-1693.
10. Roman S, Cenni JC, Roy P, et al: Value of rectal ultrasound in predicting staging and outcome in patients with rectal adenocarcinoma. Dis Colon Rectum 2004;47:1323-1330.
11. Phillips R, Hittinger R, Blesovsky L: Large bowel cancer: surgical pathology and its relationship to survival. Br J Surg 1984;7:604-610.
12. Chapuis P, Deut O, Fisher R: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985;72:698-702.
13. Wiggers T, Arends J, Schutte B, et al: A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 1988;61:386-395.
14. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001;28(suppl 1):20-24.
15. Galizia G, Orditura M, Romano C, et al: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002;102:169-178.
16. Funaioli C, Pinto C, Mutri V, Di Fabio F, Ceccarelli C, Martoni AA: Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value? Clin Colorectal Cancer 2006;6:38-45.
17. Bazan V, Migliavacca M, Zanna I, et al: DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients: result of a 5-year prospective study. Cancer Res Clin Oncol 2002;128:650-658.
18. Cohen C: Image cytometric analysis in pathology. Hum Pathol 1996;27:482-493.
19. Millot C, Dufer J: Clinical applications of image cytometry to human tumour analysis. Histol Histopathol 2000;15:1185-1200.
20. Salud A, Porcel JM, Raikundalia B, Camplejohn RS, Taub NA: Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer. J Surg Oncol 1999;72:167-174.
21. Haydon AM, Jass JR: Emerging pathways in colorectal-cancer development. Lancet Oncol 2002;3:83-88.
22. Jass JR, Young J, Leggett BA: Evolution of colorectal cancer: change of pace and change of direction. J Gastroenterol Hepatol 2002;17:17-26.
23. Gervaz P, Bucher P, Morel P: Two colons - two cancers: paradigm shift and clinical implications. J Surg Oncol 2004;88:261-266.
24. Jass JR, Whitehall VL, Young J, Leggett BA: Emerging concepts in colorectal neoplasia. Gastroenterology 2002;123:862-876.
25. Armitage NC, Robins RA, Evans DF, Turner DR, Baldwin RW, Hardcastle JD: The influence of tumour cell DNA abnormalities on survival in colorectal cancer. Br J Surg 1985;72:828-830.
26. Kokal W, Sheibani K, Terz J, Harada JR: Tumour DNA content in the prognosis of colorectal carcinoma. JAMA 1986;13;255:3123-3127.
27. Fausel RE, Burleigh W, Kaminsky DB: DNA quantification in colorectal carcinoma using flow and image analysis cytometry. Anal Quant Cytol Histol 1990;12:21-27.
28. Melamed MR, Enker WE, Banner P, Janov AJ, Kessler G, Darzynkiewicz Z: Flow cytometry of colorectal carcinoma with three-year follow-up. Dis Colon Rectum 1986;29:184-186.
29. Suzuki H, Matsumoto K, Masuda T, Koike H: DNA ploidy of colorectal carcinoma: correlation with conventional prognostic variables. J Clin Gastroenterol 1988;10:176-178.
30. Bottger TC, Potratz D, Stockle M, Wellek S, Klupp J, Junginger T: Prognostic value of DNA analysis in colorectal carcinoma. Cancer 1993;15;72:3579-3587.
31. Buhmeida A, Ålgars A, Ristamäki R, Collan Y, Syrjänen K, Pyrhönen S: Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma. Anticancer Res 2006;26:455-462.
32. Hedley DW, Friedlander ML, Taylor IW: Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 1985;6:327-333.
33. Gaub J, Auer GU, Zetterberg A: Quantitative cytological aspects of a combined Feulgen naphthol yellow S staining procedure for the simultaneous determinatins of nuclear and cytoplasmic protein and DNA in mammalian cells. Exp Cell Res 1975;92:323-332.
34. Bohnhoff GL: Setting up proper illumination on your microscope. Am J Med Technol 1979;45:650-651.
35. Bendardaf R, Lamlum H, Ristamaki R, Algars A, Collan Y, Pyrhonen S: Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content. Oncology 2004;66:46-52.
36. Buhmeida A, Collan Y, Syrjänen K, Pyrhönen S: DNA image cytometry for prognostication of colorectal cancer: technical comments on the performance of DNA cytometry and interpretation of histograms. Image Anal Stereol 2006;25:1-12.
37. Cascinu S, Staccioli MP, Gasparini G, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000;6:2803-2807.
38. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-250.
39. Benson AB, Schrag D, Somerfield M, et al: American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. J Clin Oncol 2004;15:3408-3419.
40. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995 1;122:321-326.
41. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355.
42. Harrington DP: The tea leaves of small trials. J Clin Oncol 1999;17:1336-1338.
43. Venook AP: Status of adjuvant chemotherapy for stage II colon cancer. Am Soc Clin Oncol 40th Annu Meet, New Orleans, June 5-8, 2004, p 81.184.
44. Silvestrini R: Relevance of DNA-ploidy as a prognostic instrument for solid tumours. Ann Oncol 2000;11:259-261.
45. Scott NA, Wieand HS, Moertel CG, Cha SS, Beart RW, Lieber MM: Colorectal cancer: Dukes' stage, tumour site, preoperative plasma CEA level, and patient prognosis related to tumour DNA ploidy pattern. Arch Surg 1987;122:1375-1379.
46. Witzig TE, Loprinzi CL, Gonchoroff NJ, et al: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991;15;68:879-888.
47. Lanza G, Gafa R, Santini A, et al: Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 1998;82:49-59.
48. Zarbo RJ, Nakhleh RE, Brown RD, Kubus JJ, Ma CK, Mackowiak P: Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry. Cancer 1997;1;79:2073-2086.
49. Tonouchi H, Matsumoto K, Kinoshita T, Itoh H, Suzuki H: Prognostic value of DNA ploidy patterns of colorectal adenocarcinoma: univariate and multivariate analysis. Dig Surg 1998;15:687-692.
50. Bufill JA: Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumour location. Ann Intern Med 1990;15;113:779-788.
51. Jen J, Kim H, Piantadosi S, et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;28;331:213-221.
52. Hamelin R, Laurent-Puig P, Olschwang S, et al: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-48.
53. Bosari S, Lee AK, Wiley BD, Heatley GJ, Silverman ML: Flow cytometric and image analyses of colorectal adenocarcinomas: a comparative study with clinical correlations. Am J Clin Pathol 1993;99:187-194.
54. Lanza G Jr, Maestri I, Ballotta MR, Dubini A, Cavazzini L: Relationship of nuclear DNA content to clinicopathologic features in colorectal cancer. Mod Pathol 1994;7:161-165.
55. Delattre O, Olschwang S, Law DJ, et al: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;ii:353-356.
56. Offerhaus GJ, De Feyter EP, Cornelisse CJ, et al: The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-1619.
57. Lothe RA, Peltomaki P, Meling GI, et al: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-5852.
58. Bocker T, Schlegel J, Kullmann F, et al: Genomic instability in colorectal carcinomas: comparison of different evaluation methods and their biological significance. J Pathol 1996;179:15-19.
59. Sieber OM, Heinimann K, Gorman P, et al: Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC. Proc Natl Acad Sci USA 2002;99:16910-16915.
60. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP: Microsatellite instability in colorectal cancer. Br J Surg 2006;93:395-406.